Please login to the form below

Not currently logged in
Email:
Password:

Pharma in 2020

New virtual reality technology may lead to the cost and length of clinical trials falling significantly by the year 2020
New virtual reality technology may lead to the cost and length of clinical trials falling significantly by the year 2020, according to a report form global consultancy, PriceWaterhouseCooper (PWC), that says pharma must do more to secure its future.

PWC's report, Pharma 2020: virtual R&D, says that the process of testing, researching and developing new drugs could be cut by two thirds and that success and approval rates could rise dramatically.

Steve Arlington, PWC global pharmaceutical and life sciences industry advisor leader, explained that making incremental improvements to the R&D process is no longer enough to counter the plummeting productivity of effective novel treatments.

"The resulting commercial deficit in pharma has enormous implications for the industry, society and governments as a whole," he said.

"To remain at the forefront of medical research, help patients live longer healthier lives and deliver the revenue returns shareholders have come to expect, pharma needs a faster, more predictive way of testing molecules before they go into humans."

The main idea being put forward by the PWC report is the creation of what it terms the 'Virtual Man.' By using existing technologies and data, it could be possible to create a computer-based model of the human body that could be used to test drugs in a virtual state. Academics around the world are already engaged in producing models of the heart, organs, cell systems and musculoskeletal structures.

According to PWC, the necessary in-depth information about the human body and its diseases could be acquired through an international collaborative knowledge-sharing network between pharmaceutical companies, academic institutions and independent research houses.

Some companies have already employed virtual technologies and have been able to reduce clinical trial times by 40 per cent. Anthony Farino, of PWC's US pharmaceutical and life sciences advisory leaders department, said that advances in drug testing could deliver substantial savings, halve drug development times and reduce costs per drug.

"New technologies can play a major role in helping pharmaceutical companies move forward, enhancing their ability to produce treatments that deliver measurable improvements in safety, efficacy and ease of compliance," he said.

However, he noted that "technology is not the answer to all pharma's problems. Many companies as well as the infrastructure of regulators and vendors that support the industry will have to make significant strategic, organisational and behavioural changes."

25th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics